Important Notice for Shareholders of Sana Biotechnology, Inc.
New York, NY, March 31, 2025 – The Gross Law Firm, a leading national securities fraud law firm, issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).
If you purchased or acquired the shares of Sana Biotechnology, Inc. (the “Company”) between February 1, 2023, and December 31, 2024, inclusive (the “Class Period”), you may have been harmed by the Company’s securities fraud, and you are encouraged to contact the firm.
Alleged Securities Fraud
The Gross Law Firm is investigating potential securities fraud claims on behalf of shareholders of Sana Biotechnology, Inc. The investigation focuses on whether the Company and certain of its officers and/or directors violated federal securities laws.
During the Class Period, Sana Biotechnology, Inc. made false and/or misleading statements and/or failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, the Company misrepresented the commercial prospects of its cell therapy product candidate, which was undergoing clinical trials.
Lead Plaintiff Appointment
If you are a shareholder who purchased or acquired the shares of Sana Biotechnology, Inc. during the Class Period and suffered a loss, you may be entitled to serve as the lead plaintiff in this action. The lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Contact the Firm
To learn more about this investigation and your potential role as a lead plaintiff, please contact The Gross Law Firm as soon as possible at 888-227-1050, 212-509-1850, or email [email protected]. You may also fill out the contact form on our website: https://www.grosslawfirm.com/contact/.
Effect on Individual Investors
If the allegations of securities fraud are proven, shareholders who purchased or acquired Sana Biotechnology, Inc. shares during the Class Period may be entitled to recover their losses, including any damages or losses sustained as a result of the fraud.
Effect on the World
The potential securities fraud at Sana Biotechnology, Inc. is a reminder of the importance of transparency and honesty in the business world. Such fraudulent activities not only harm individual investors but also undermine confidence in the stock market and the economy as a whole.
Conclusion
The Gross Law Firm is committed to helping its clients recover their losses due to securities fraud. If you believe you have been harmed by Sana Biotechnology, Inc.’s alleged securities fraud during the Class Period, contact the firm as soon as possible to discuss your potential role as a lead plaintiff in this action.
At a time when the biotechnology sector is rapidly advancing, it is crucial for companies to maintain transparency and honesty in their reporting and communications with investors. The potential securities fraud at Sana Biotechnology, Inc. underscores the need for heightened vigilance and scrutiny in the investment community.
For further information about The Gross Law Firm and its representation of Sana Biotechnology, Inc. shareholders, please visit https://www.grosslawfirm.com/cases/sana-biotechnology/.
About The Gross Law Firm
The Gross Law Firm is a leading national securities fraud law firm representing investors throughout the world in securities litigation and arbitration. The firm’s attorneys have extensive experience in prosecuting securities fraud, and its attorneys have recovered billions of dollars for investors.
